NCT03197584.

Trial name or title	NANT ovarian cancer vaccine: combination immunotherapy in subjects with epithelial ovarian cancer who have progressed on or after standard‐of‐care (SoC) therapy
Methods	Uncontrolled phase Ib/II
Participants	67 participants with epithelial ovarian cancer
Interventions	Avelumab, bevacizumab, capecitabine, cyclophosphamide, 5‐fluorouracil, fulvestrant, leucovorin, paclitaxel, omega‐3‐acid ethyl esters, oxaliplatin, stereotactic body radiation therapy, ALT‐803, ETBX‐021, ETBX‐051, ETBX‐061, GI‐4000, GI‐6301, and hank
Outcomes	Adverse events Response rate (RECIST) Immune response
Starting date	June 2017
Contact information
Notes	Not yet recruiting, October 2017